You won't find many stocks that have been more volatile this year than Inovio Pharmaceuticals (NASDAQ: INO). We're talking about a biotech that saw its share price skyrocket more than 300% by early March, only to lose more than half of those gains within a matter of days. Just last month, Inovio's shares nearly doubled before plunging yet again.
Some investors have probably thrown in the towel on the beaten-down biotech stock. But could Inovio actually be a buy on bad news?
Image source: Getty Images.
Source Fool.com